
Eli Lilly and Company, Novo Nordisk A/S, and Bristol Myers Squibb are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related therapies. For investors, they offer exposure to healthcare innovation and potential high returns but carry risks tied to clinical trial outcomes, regulatory approvals, patent expirations, drug pricing and reimbursement policies, and sector-specific M&A activity. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Read Our Latest Research Report on NVO
Bristol Myers Squibb (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read Our Latest Research Report on BMY
Read More
- MarketBeat’s Top Five Stocks to Own in December 2025
- Uber Gets a Street-High Upgrade as Robotaxis Roll Out in Dallas
- Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It
- Can Alibaba’s Big Bets Pay Off After a Breakout Year?
- How Accenture’s OpenAI Partnership Turns AI Hype Into Profits
- Battle of the Big-Upside Tech Names: HUBS vs. NBIS vs. TEAM
